Tetsuhiro Yamakado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tetsuhiro Yamakado has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Shinya Tanaka
Department of Cancer Pathology, Faculty of Medicine Hokkaido University Sapporo Japan
3 shared publications - Zen-Ichi Tanei
Department of Surgical Pathology Hokkaido University Hospital Sapporo Japan
3 shared publications Taichi Kimura
Department of Pathology National Hospital Organization, Hokkaido Medical Center Hokkaido Japan
2 shared publications- Hanako Sato-Yazawa
Department of Pathology, Dokkyo Medical University School of Medicine and Graduate School of Medicine, Mibu-machi, Tochigi, Japan
1 shared publication - Jun Ishii
Department of Pathology, Dokkyo Medical University School of Medicine and Graduate School of Medicine, Mibu-machi, Tochigi, Japan
1 shared publication - Koki Ise
Department of Cancer Pathology, Faculty of Medicine Hokkaido University Sapporo Japan
1 shared publication
Latest Publications
- Open Access
- 18 March 2026
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 52 (2) , e70068
Myofibre Density Reveals a Critical Threshold Around Age 6 in Steroid‐Naïve Duchenne Muscular Dystrophy: A Retrospective Observational Study
Aims: In Duchenne muscular dystrophy (DMD), robust histological markers for assessing early disease progression remain elusive. We defined myofibre density ( MFD ) as the count of myofibres per square millimetre, which, in our preliminary survey of DMD muscle biopsies, steeply declined with age (Spearman's ρ : −0.85). We aimed to characterise age‐dependent MFD dynamics in early‐stage DMD. Methods: We retrospectively assessed 46 archival muscle‐biopsy slides (steroid‐naïve; collected > 40 years ago) using semi‐quantitative image analysis with digital restoration. MFD and classical histological variables were quantified. Age– MFD dynamics were modelled with segmented regression and validated using weakly informative Bayesian modelling. The primary measure was the MFD age‐breakpoint. Secondary measures included breakpoint‐detection power, age‐predictive MFD cut‐offs and behaviour of conventional variables across breakpoint‐defined age bands. Results: After quality and age‐distribution screening, 35 slides (age 1–11 years) were analysed. Segmented regression identified a breakpoint at 6.25 years (95% confidence interval [CI]: 5.08–7.42); after which MFD plateaued at lower levels. Bayesian posterior estimate was 6.37 years (95% credible interval: 5.24–7.66). A 10,000‐run Monte Carlo simulation ( n = 35) showed approximately 80% power to recapture the breakpoint within ±1.25 years. MFD cut‐offs > 596 and < 426 fibres/mm 2 corresponded to 80% and 20% probabilities of age < 6.25 years. Between the early (< 5 years) and late (≥ 7.5 years) age bands defined by the breakpoint–CI limits, myofibre‐size parameters, myofibre area and fat replacement shifted significantly. Conclusions: MFD , a simple metric, reveals a previously unrecognised phase of rapid myofibre loss lasting up to around age 6 in early‐stage DMD.
- 18 March 2026
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 52 (2) , e70068
Open AccessMyofibre Density Reveals a Critical Threshold Around Age 6 in Steroid‐Naïve Duchenne Muscular Dystrophy: A Retrospective Observational Study
Aims: In Duchenne muscular dystrophy (DMD), robust histological markers for assessing early disease progression remain elusive. We defined myofibre density ( MFD ) as the count of myofibres per square millimetre, which, in our preliminary survey of DMD muscle biopsies, steeply declined with age (Spearman's ρ : −0.85). We aimed to characterise age‐dependent MFD dynamics in early‐stage DMD. Methods: We retrospectively assessed 46 archival muscle‐biopsy slides (steroid‐naïve; collected > 40 years ago) using semi‐quantitative image analysis with digital restoration. MFD and classical histological variables were quantified. Age– MFD dynamics were modelled with segmented regression and validated using weakly informative Bayesian modelling. The primary measure was the MFD age‐breakpoint. Secondary measures included breakpoint‐detection power, age‐predictive MFD cut‐offs and behaviour of conventional variables across breakpoint‐defined age bands. Results: After quality and age‐distribution screening, 35 slides (age 1–11 years) were analysed. Segmented regression identified a breakpoint at 6.25 years (95% confidence interval [CI]: 5.08–7.42); after which MFD plateaued at lower levels. Bayesian posterior estimate was 6.37 years (95% credible interval: 5.24–7.66). A 10,000‐run Monte Carlo simulation ( n = 35) showed approximately 80% power to recapture the breakpoint within ±1.25 years. MFD cut‐offs > 596 and < 426 fibres/mm 2 corresponded to 80% and 20% probabilities of age < 6.25 years. Between the early (< 5 years) and late (≥ 7.5 years) age bands defined by the breakpoint–CI limits, myofibre‐size parameters, myofibre area and fat replacement shifted significantly. Conclusions: MFD , a simple metric, reveals a previously unrecognised phase of rapid myofibre loss lasting up to around age 6 in early‐stage DMD.
- 27 January 2025
- Published by Wiley in Pathology International
- Vol. 75 (2) , 105-113
Spontaneous Transformation from Lung Adenocarcinoma to MYC‐amplified Large Cell Neuroendocrine Carcinoma
Recent studies suggest that lung adenocarcinoma cells are closely associated with the tumorigenesis of large‐cell neuroendocrine carcinoma via cellular transformation. However, morphological evidence, along with genetic abnormalities before, during, and after transformation, is quite limited. We present here a case of combined large‐cell neuroendocrine carcinoma and adenocarcinoma exhibiting acinar and solid patterns. Adenocarcinoma cells with abundant mucin, exhibiting positivity for both napsin‐A and neuroendocrine markers, were partially found in the acinar adenocarcinoma component and extensively observed in the solid adenocarcinoma component. Next‐generation sequencing using extracted genomic DNA from the three components revealed homozygous TP53 (missense) and STK11 (nonsense) mutations in all three components, suggesting monoclonal origin. Furthermore, MYC gene amplification, recently presumed to be a pivotal driver in neuroendocrine transformation, was observed in both the solid adenocarcinoma and large‐cell neuroendocrine carcinoma components. These genetic findings corresponded to pre‐ and post‐transformation morphology, providing compelling evidence that some kinds of adenocarcinomas may serve as a precursor of large‐cell neuroendocrine carcinoma.
- 27 January 2025
- Published by Wiley in Pathology International
- Vol. 75 (2) , 105-113
Spontaneous Transformation from Lung Adenocarcinoma to MYC‐amplified Large Cell Neuroendocrine Carcinoma
Recent studies suggest that lung adenocarcinoma cells are closely associated with the tumorigenesis of large‐cell neuroendocrine carcinoma via cellular transformation. However, morphological evidence, along with genetic abnormalities before, during, and after transformation, is quite limited. We present here a case of combined large‐cell neuroendocrine carcinoma and adenocarcinoma exhibiting acinar and solid patterns. Adenocarcinoma cells with abundant mucin, exhibiting positivity for both napsin‐A and neuroendocrine markers, were partially found in the acinar adenocarcinoma component and extensively observed in the solid adenocarcinoma component. Next‐generation sequencing using extracted genomic DNA from the three components revealed homozygous TP53 (missense) and STK11 (nonsense) mutations in all three components, suggesting monoclonal origin. Furthermore, MYC gene amplification, recently presumed to be a pivotal driver in neuroendocrine transformation, was observed in both the solid adenocarcinoma and large‐cell neuroendocrine carcinoma components. These genetic findings corresponded to pre‐ and post‐transformation morphology, providing compelling evidence that some kinds of adenocarcinomas may serve as a precursor of large‐cell neuroendocrine carcinoma.
- 17 July 2024
- Published by Wiley in Pathology International
- Vol. 74 (8) , 489-492
Sporadic gastric foveolar‐type adenoma with morular metaplasia
- 17 July 2024
- Published by Wiley in Pathology International
- Vol. 74 (8) , 489-492
Sporadic gastric foveolar‐type adenoma with morular metaplasia